CL2023002704A1 - Inhibidores heterocíclicos de la cinasa rip1 - Google Patents
Inhibidores heterocíclicos de la cinasa rip1Info
- Publication number
- CL2023002704A1 CL2023002704A1 CL2023002704A CL2023002704A CL2023002704A1 CL 2023002704 A1 CL2023002704 A1 CL 2023002704A1 CL 2023002704 A CL2023002704 A CL 2023002704A CL 2023002704 A CL2023002704 A CL 2023002704A CL 2023002704 A1 CL2023002704 A1 CL 2023002704A1
- Authority
- CL
- Chile
- Prior art keywords
- heterocyclic
- kinase inhibitors
- rip1 kinase
- inhibitor compounds
- rip1
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 3
- 102100021559 KRR1 small subunit processome component homolog Human genes 0.000 title abstract 2
- 101150040948 RIP1 gene Proteins 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 abstract 2
- 101710138589 Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 101000971351 Homo sapiens KRR1 small subunit processome component homolog Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
En la presente descripción se describen compuestos inhibidores de cinasa, tales como compuestos inhibidores de proteína 1 cinasa que interactúa con el receptor (RIP1), de la Fórmula (I), así como también composiciones farmacéuticas y combinaciones que comprenden tales compuestos inhibidores. Los compuestos, composiciones farmacéuticas, y/o combinaciones descritas pueden usarse para tratar o prevenir una enfermedad o afección asociada a cinasas, particularmente una enfermedad o afección asociada a RIP 1.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163159970P | 2021-03-11 | 2021-03-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2023002704A1 true CL2023002704A1 (es) | 2024-03-22 |
Family
ID=81327717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2023002704A CL2023002704A1 (es) | 2021-03-11 | 2023-09-11 | Inhibidores heterocíclicos de la cinasa rip1 |
Country Status (18)
Country | Link |
---|---|
US (1) | US20220296608A1 (es) |
EP (1) | EP4304713A1 (es) |
JP (1) | JP2024509466A (es) |
KR (1) | KR20230144575A (es) |
CN (1) | CN117083270A (es) |
AR (1) | AR125587A1 (es) |
AU (1) | AU2022232927A1 (es) |
BR (1) | BR112023018167A2 (es) |
CA (1) | CA3211778A1 (es) |
CL (1) | CL2023002704A1 (es) |
CO (1) | CO2023012077A2 (es) |
CR (1) | CR20230438A (es) |
DO (1) | DOP2023000186A (es) |
EC (1) | ECSP23068893A (es) |
IL (1) | IL305456A (es) |
PE (1) | PE20240237A1 (es) |
TW (1) | TW202300490A (es) |
WO (1) | WO2022192533A1 (es) |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5087240A (en) | 1983-08-18 | 1992-02-11 | Drug Delivery Systems Inc. | Transdermal drug patch with conductive fibers |
US4921475A (en) | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
US4738851A (en) | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
US5163899A (en) | 1987-03-20 | 1992-11-17 | Drug Delivery Systems Inc. | Transdermal drug delivery system |
US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
GB8804164D0 (en) | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
US4882150A (en) | 1988-06-03 | 1989-11-21 | Kaufman Herbert E | Drug delivery system |
US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
US5088977A (en) | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
US5521222A (en) | 1989-09-28 | 1996-05-28 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
IE66203B1 (en) | 1989-12-04 | 1995-12-13 | Searle & Co | System for transdermal albuterol administration |
US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
US5077033A (en) | 1990-08-07 | 1991-12-31 | Mediventures Inc. | Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide |
DE69212850T2 (de) | 1991-01-15 | 1997-03-06 | Alcon Lab Inc | Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen |
US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
JPH07502219A (ja) | 1991-12-18 | 1995-03-09 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | 多重層型バリアー構造体 |
ATE132381T1 (de) | 1992-01-29 | 1996-01-15 | Voelkl Franz Ski | Ballspielschläger, insbesondere tennisschläger |
IL114193A (en) | 1994-06-20 | 2000-02-29 | Teva Pharma | Ophthalmic pharmaceutical compositions based on sodium alginate |
ES2094688B1 (es) | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
IT1283911B1 (it) | 1996-02-05 | 1998-05-07 | Farmigea Spa | Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo |
US5800807A (en) | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
US6261547B1 (en) | 1998-04-07 | 2001-07-17 | Alcon Manufacturing, Ltd. | Gelling ophthalmic compositions containing xanthan gum |
US6197934B1 (en) | 1998-05-22 | 2001-03-06 | Collagenesis, Inc. | Compound delivery using rapidly dissolving collagen film |
US8922322B2 (en) * | 2012-08-31 | 2014-12-30 | Delta Electronics, Inc. | Combined structure of hollow bobbin and conductive sheet, hollow bobbin, and conductive sheet |
TWI637951B (zh) * | 2013-02-15 | 2018-10-11 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 |
US20170266199A1 (en) * | 2014-08-21 | 2017-09-21 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as rip1 kinase inhibitors as medicaments |
MY192762A (en) * | 2015-07-02 | 2022-09-07 | Hoffmann La Roche | Bicyclic lactams and methods of use thereof |
CN109071504B (zh) * | 2016-02-05 | 2022-03-08 | 戴纳立制药公司 | 受体相互作用蛋白激酶1的抑制剂 |
CN111138448B (zh) * | 2018-11-02 | 2022-08-02 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
JP7045526B2 (ja) * | 2018-11-02 | 2022-03-31 | 中国科学院上海薬物研究所 | Rip1キナーゼを阻害する複素環状アミド及びその使用 |
CA3149963A1 (en) * | 2019-09-06 | 2021-03-11 | Simon Shaw | Heterocyclic rip1 kinase inhibitors |
BR112022010082A2 (pt) * | 2019-11-26 | 2022-08-30 | Univ Texas | Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica |
-
2022
- 2022-03-02 TW TW111107595A patent/TW202300490A/zh unknown
- 2022-03-02 AR ARP220100461A patent/AR125587A1/es unknown
- 2022-03-10 BR BR112023018167A patent/BR112023018167A2/pt unknown
- 2022-03-10 CR CR20230438A patent/CR20230438A/es unknown
- 2022-03-10 WO PCT/US2022/019744 patent/WO2022192533A1/en active Application Filing
- 2022-03-10 EP EP22714650.3A patent/EP4304713A1/en active Pending
- 2022-03-10 CN CN202280020689.7A patent/CN117083270A/zh active Pending
- 2022-03-10 AU AU2022232927A patent/AU2022232927A1/en active Pending
- 2022-03-10 PE PE2023002567A patent/PE20240237A1/es unknown
- 2022-03-10 CA CA3211778A patent/CA3211778A1/en active Pending
- 2022-03-10 US US17/691,596 patent/US20220296608A1/en active Pending
- 2022-03-10 IL IL305456A patent/IL305456A/en unknown
- 2022-03-10 KR KR1020237030350A patent/KR20230144575A/ko active Search and Examination
- 2022-03-10 JP JP2023555403A patent/JP2024509466A/ja active Pending
-
2023
- 2023-09-11 DO DO2023000186A patent/DOP2023000186A/es unknown
- 2023-09-11 CL CL2023002704A patent/CL2023002704A1/es unknown
- 2023-09-11 EC ECSENADI202368893A patent/ECSP23068893A/es unknown
- 2023-09-12 CO CONC2023/0012077A patent/CO2023012077A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP23068893A (es) | 2023-10-31 |
CA3211778A1 (en) | 2022-09-15 |
AR125587A1 (es) | 2023-08-02 |
DOP2023000186A (es) | 2023-11-30 |
BR112023018167A2 (pt) | 2023-10-31 |
PE20240237A1 (es) | 2024-02-16 |
AU2022232927A1 (en) | 2023-08-17 |
WO2022192533A1 (en) | 2022-09-15 |
CN117083270A (zh) | 2023-11-17 |
CR20230438A (es) | 2024-01-16 |
US20220296608A1 (en) | 2022-09-22 |
KR20230144575A (ko) | 2023-10-16 |
JP2024509466A (ja) | 2024-03-01 |
TW202300490A (zh) | 2023-01-01 |
EP4304713A1 (en) | 2024-01-17 |
CO2023012077A2 (es) | 2024-01-15 |
IL305456A (en) | 2023-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2022000051A (es) | Compuestos inhibidores de rip1 y métodos para hacer y utilizar los mismos | |
CL2022002695A1 (es) | Inhibidores de rip1k | |
DOP2023000169A (es) | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos | |
CL2019002777A1 (es) | Compuestos que inhiben la proteína mcl-1. | |
ECSP20077518A (es) | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos | |
DOP2022000042A (es) | Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos | |
CL2017000469A1 (es) | Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1 | |
DOP2018000241A (es) | Derivados aromáticos de sulfonamida | |
CO2022015638A2 (es) | Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso | |
CL2022003812A1 (es) | Inhibidores de rip1k | |
AR058338A1 (es) | Derivados de pirrol fusionado, composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la quinasa. | |
MX2022005509A (es) | Compuestos inhibidores de rip1 heterociclicos. | |
CO2021011023A2 (es) | Compuesto heterocíclico, composición farmacéutica que lo comprende, método para su preparación, y uso de estos | |
CO2023012077A2 (es) | Inhibidores heterocíclicos de la cinasa rip1 | |
ECSP22083926A (es) | Compuestos útiles para inhibir la quinasa ret | |
AR120412A1 (es) | Compuestos heterocíclicos inhibidores de rip1 | |
UY38133A (es) | Nuevos inhibidores de cdk8/19 | |
AR113817A1 (es) | Compuestos útiles para inhibir a cdk7 | |
CU20200020A7 (es) | Composición farmacéutica que comprende abx196 |